FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ABR-YWHAE

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ABR-YWHAE
FusionPDB ID: 564
FusionGDB2.0 ID: 564
HgeneTgene
Gene symbol

ABR

YWHAE

Gene ID

29

7531

Gene nameABR activator of RhoGEF and GTPasetyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon
SynonymsMDB14-3-3E|HEL2|KCIP-1|MDCR|MDS
Cytomap

17p13.3

17p13.3

Type of geneprotein-codingprotein-coding
Descriptionactive breakpoint cluster region-related proteinABR, RhoGEF and GTPase activating proteinactive BCR-related14-3-3 protein epsilon14-3-3 epsilonepididymis luminal protein 2mitochondrial import stimulation factor L subunitprotein kinase C inhibitor protein-1tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon polypeptidetyrosine
Modification date2020031320200327
UniProtAcc

Q15018

Main function of 5'-partner protein: FUNCTION: Component of the BRISC complex, a multiprotein complex that specifically cleaves 'Lys-63'-linked polyubiquitin, leaving the last ubiquitin chain attached to its substrates (PubMed:19214193, PubMed:20032457, PubMed:20656690, PubMed:24075985). May act as a central scaffold protein that assembles the various components of the BRISC complex and retains them in the cytoplasm (PubMed:20656690). Plays a role in regulating the onset of apoptosis via its role in modulating 'Lys-63'-linked ubiquitination of target proteins (By similarity). Required for normal mitotic spindle assembly and microtubule attachment to kinetochores via its role in deubiquitinating NUMA1 (PubMed:26195665). Plays a role in interferon signaling via its role in the deubiquitination of the interferon receptor IFNAR1; deubiquitination increases IFNAR1 activities by enhancing its stability and cell surface expression (PubMed:24075985, PubMed:26344097). Down-regulates the response to bacterial lipopolysaccharide (LPS) via its role in IFNAR1 deubiquitination (PubMed:24075985). Required for normal induction of p53/TP53 in response to DNA damage (PubMed:25283148). Independent of the BRISC complex, promotes interaction between USP7 and p53/TP53, and thereby promotes deubiquitination of p53/TP53, preventing its degradation and resulting in increased p53/TP53-mediated transcription regulation and p53/TP53-dependent apoptosis in response to DNA damage (PubMed:25283148). {ECO:0000250|UniProtKB:Q3TCJ1, ECO:0000269|PubMed:19214193, ECO:0000269|PubMed:20032457, ECO:0000269|PubMed:20656690, ECO:0000269|PubMed:24075985, ECO:0000269|PubMed:25283148}.

P62258

Main function of 5'-partner protein: FUNCTION: Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner (By similarity). Positively regulates phosphorylated protein HSF1 nuclear export to the cytoplasm (PubMed:12917326). {ECO:0000250|UniProtKB:P62261, ECO:0000269|PubMed:12917326}.
Ensembl transtripts involved in fusion geneENST idsENST00000291107, ENST00000302538, 
ENST00000544583, ENST00000574437, 
ENST00000536794, ENST00000543210, 
ENST00000572441, ENST00000573895, 
ENST00000571732, ENST00000498643, 
ENST00000573026, ENST00000575977, 
ENST00000264335, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score23 X 15 X 14=483025 X 13 X 12=3900
# samples 3632
** MAII scorelog2(36/4830*10)=-3.74595437739346
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(32/3900*10)=-3.60733031374961
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ABR [Title/Abstract] AND YWHAE [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ABR [Title/Abstract] AND YWHAE [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ABR(1132087)-YWHAE(1268352), # samples:9
YWHAE(1303340)-ABR(1028702), # samples:2
Anticipated loss of major functional domain due to fusion event.ABR-YWHAE seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ABR-YWHAE seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ABR-YWHAE seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF.
ABR-YWHAE seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF.
ABR-YWHAE seems lost the major protein functional domain in Tgene partner, which is a epigenetic factor due to the frame-shifted ORF.
YWHAE-ABR seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF.
YWHAE-ABR seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF.
YWHAE-ABR seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneABR

GO:0090630

activation of GTPase activity

7479768

TgeneYWHAE

GO:0000165

MAPK cascade

12917326

TgeneYWHAE

GO:0034605

cellular response to heat

12917326

TgeneYWHAE

GO:0046827

positive regulation of protein export from nucleus

12917326

TgeneYWHAE

GO:0051480

regulation of cytosolic calcium ion concentration

18029012

TgeneYWHAE

GO:0060306

regulation of membrane repolarization

11953308

TgeneYWHAE

GO:1901016

regulation of potassium ion transmembrane transporter activity

11953308

TgeneYWHAE

GO:1901020

negative regulation of calcium ion transmembrane transporter activity

18029012

TgeneYWHAE

GO:1902309

negative regulation of peptidyl-serine dephosphorylation

11953308

TgeneYWHAE

GO:1905913

negative regulation of calcium ion export across plasma membrane

18029012



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr17:1132087/chr17:1268352)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ABR (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across YWHAE (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000302538ABRchr17982570-ENST00000264335YWHAEchr171268352-27268471471550467
ENST00000574437ABRchr17982570-ENST00000264335YWHAEchr171268352-290610271231730535
ENST00000291107ABRchr17982570-ENST00000264335YWHAEchr171268352-2500621321324430
ENST00000302538ABRchr17982569-ENST00000264335YWHAEchr171268352-27268471471550467
ENST00000574437ABRchr17982569-ENST00000264335YWHAEchr171268352-290610271231730535
ENST00000291107ABRchr17982569-ENST00000264335YWHAEchr171268352-2500621321324430

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000302538ENST00000264335ABRchr17982570-YWHAEchr171268352-0.0005294690.99947053
ENST00000574437ENST00000264335ABRchr17982570-YWHAEchr171268352-0.0005785770.9994215
ENST00000291107ENST00000264335ABRchr17982570-YWHAEchr171268352-0.0005854990.99941456
ENST00000302538ENST00000264335ABRchr17982569-YWHAEchr171268352-0.0005294690.99947053
ENST00000574437ENST00000264335ABRchr17982569-YWHAEchr171268352-0.0005785770.9994215
ENST00000291107ENST00000264335ABRchr17982569-YWHAEchr171268352-0.0005854990.99941456

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ABR-YWHAE

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ABRchr17982569YWHAEchr1712683521027301KDSKDSHTSVTMEEMVESMKKVAGMD
ABRchr17982569YWHAEchr171268352621196KDSKDSHTSVTMEEMVESMKKVAGMD
ABRchr17982569YWHAEchr171268352847233KDSKDSHTSVTMEEMVESMKKVAGMD
ABRchr17982570YWHAEchr1712683521027301KDSKDSHTSVTMEEMVESMKKVAGMD
ABRchr17982570YWHAEchr171268352621196KDSKDSHTSVTMEEMVESMKKVAGMD
ABRchr17982570YWHAEchr171268352847233KDSKDSHTSVTMEEMVESMKKVAGMD

Top

Potential FusionNeoAntigen Information of ABR-YWHAE in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ABR-YWHAE_982569_1268352.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ABR-YWHAEchr17982569chr171268352621HLA-B18:01MEEMVESM0.99720.77781119
ABR-YWHAEchr17982569chr171268352621HLA-B39:01SHTSVTMEEM0.99750.8799515
ABR-YWHAEchr17982569chr171268352621HLA-B38:02SHTSVTMEEM0.99640.9469515
ABR-YWHAEchr17982569chr171268352621HLA-B38:01SHTSVTMEEM0.99620.9469515
ABR-YWHAEchr17982569chr171268352621HLA-B15:10SHTSVTMEEM0.99430.6203515
ABR-YWHAEchr17982569chr171268352621HLA-B15:18SHTSVTMEEM0.97780.7737515
ABR-YWHAEchr17982569chr171268352621HLA-B44:03EEMVESMKKV0.96220.96311222
ABR-YWHAEchr17982569chr171268352621HLA-B44:05EEMVESMKKV0.96020.5131222
ABR-YWHAEchr17982569chr171268352621HLA-B15:37SHTSVTMEEM0.92690.6667515
ABR-YWHAEchr17982569chr171268352621HLA-B45:01EEMVESMKKVA0.99870.97281223
ABR-YWHAEchr17982569chr171268352621HLA-B15:31TMEEMVESM0.86010.89181019
ABR-YWHAEchr17982569chr171268352621HLA-B39:09SHTSVTMEEM0.99760.5938515
ABR-YWHAEchr17982569chr171268352621HLA-B39:05SHTSVTMEEM0.99520.8559515
ABR-YWHAEchr17982569chr171268352621HLA-B18:05MEEMVESM0.99720.77781119
ABR-YWHAEchr17982569chr171268352621HLA-B18:06MEEMVESM0.99720.78751119
ABR-YWHAEchr17982569chr171268352621HLA-B18:04MEEMVESM0.99650.79011119
ABR-YWHAEchr17982569chr171268352621HLA-B18:08MEEMVESM0.99650.67921119
ABR-YWHAEchr17982569chr171268352621HLA-B18:03MEEMVESM0.99470.75751119
ABR-YWHAEchr17982569chr171268352621HLA-B18:11MEEMVESM0.99070.85861119
ABR-YWHAEchr17982569chr171268352621HLA-B38:05SHTSVTMEEM0.99620.9469515
ABR-YWHAEchr17982569chr171268352621HLA-B15:09SHTSVTMEEM0.98570.6617515
ABR-YWHAEchr17982569chr171268352621HLA-B44:07EEMVESMKKV0.96220.96311222
ABR-YWHAEchr17982569chr171268352621HLA-B44:26EEMVESMKKV0.96220.96311222
ABR-YWHAEchr17982569chr171268352621HLA-B44:13EEMVESMKKV0.96220.96311222
ABR-YWHAEchr17982569chr171268352621HLA-B39:11SHTSVTMEEM0.940.6532515

Top

Potential FusionNeoAntigen Information of ABR-YWHAE in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ABR-YWHAE_982569_1268352.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ABR-YWHAEchr17982569chr171268352621DRB1-0802MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-0804MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-0804TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-0806MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-0809MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-0820MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-0820TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-0821MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-0822MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-0824MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-0828MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-0828TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-0831MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-0831TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1101MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1103MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1104MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1104TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1105MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1106MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1106TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1108MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1109MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1110MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1112MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1113MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1115MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1118MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1118TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1124MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1125MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1125TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1127MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1128MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1129MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1132MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1133MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1134MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1135MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1135TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1137MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1138MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1138TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1139MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1141MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1142MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1142TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1143MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1143TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1144MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1144TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1146MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1146TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1147MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1147TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1149MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1150MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1150TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1151MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1154MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1154TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1156MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1156TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1157MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1157TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1158MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1158TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1159MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1160MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1160TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1161MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1162MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1163MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1166MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1167MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1167TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1172MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1174MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1175MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1176MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1177MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1177TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1178MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1178TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1180MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1181MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1183MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1183TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1184MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1184TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1185MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1187MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1188MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1188TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1189MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1190MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1191MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1192MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1192TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1193MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1194MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1195MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1196MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1204MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1209MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1305MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1306MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1306TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1307MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1309MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1311MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1311TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1314MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1318MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1318TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1324MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1326MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1342MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1342TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1344MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1347MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1350MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1356MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1360MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1362MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1406MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1412MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1415MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1415TMEEMVESMKKVAGM1025
ABR-YWHAEchr17982569chr171268352621DRB1-1417MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1420MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1421MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1427MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1429MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1433MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1434MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1437MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1452MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1473MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1474MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1480MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1481MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1483MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1484MEEMVESMKKVAGMD1126
ABR-YWHAEchr17982569chr171268352621DRB1-1484TMEEMVESMKKVAGM1025

Top

Fusion breakpoint peptide structures of ABR-YWHAE

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
3526HTSVTMEEMVESMKABRYWHAEchr17982569chr171268352621

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ABR-YWHAE

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN3526HTSVTMEEMVESMK-7.4838-7.5956
HLA-B14:023BVN3526HTSVTMEEMVESMK-3.16066-4.20376
HLA-B52:013W393526HTSVTMEEMVESMK-6.93679-7.04859
HLA-B52:013W393526HTSVTMEEMVESMK-6.10064-7.14374
HLA-A11:014UQ23526HTSVTMEEMVESMK-7.21307-7.32487
HLA-A24:025HGA3526HTSVTMEEMVESMK-6.56769-6.67949
HLA-A24:025HGA3526HTSVTMEEMVESMK-4.65311-5.69621
HLA-B44:053DX83526HTSVTMEEMVESMK-6.68002-6.79182
HLA-B44:053DX83526HTSVTMEEMVESMK-3.22493-4.26803

Top

Vaccine Design for the FusionNeoAntigens of ABR-YWHAE

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ABR-YWHAEchr17982569chr1712683521019TMEEMVESMCCATGGAAGAAATGGTGGAGTCAATGA
ABR-YWHAEchr17982569chr1712683521119MEEMVESMTGGAAGAAATGGTGGAGTCAATGA
ABR-YWHAEchr17982569chr1712683521222EEMVESMKKVAAGAAATGGTGGAGTCAATGAAGAAAGTAG
ABR-YWHAEchr17982569chr1712683521223EEMVESMKKVAAAGAAATGGTGGAGTCAATGAAGAAAGTAGCAG
ABR-YWHAEchr17982569chr171268352515SHTSVTMEEMGCCACACGTCTGTCACCATGGAAGAAATGG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ABR-YWHAEchr17982569chr1712683521025TMEEMVESMKKVAGMCCATGGAAGAAATGGTGGAGTCAATGAAGAAAGTAGCAGGGATGG
ABR-YWHAEchr17982569chr1712683521126MEEMVESMKKVAGMDTGGAAGAAATGGTGGAGTCAATGAAGAAAGTAGCAGGGATGGATG

Top

Information of the samples that have these potential fusion neoantigens of ABR-YWHAE

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LGGABR-YWHAEchr17982569ENST00000291107chr171268352ENST00000264335TCGA-HT-7693

Top

Potential target of CAR-T therapy development for ABR-YWHAE

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ABR-YWHAE

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ABR-YWHAE

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
TgeneYWHAEC0036341Schizophrenia4PSYGENET
TgeneYWHAEC0005586Bipolar Disorder2PSYGENET
TgeneYWHAEC0206630Endometrial Stromal Sarcoma2ORPHANET
TgeneYWHAEC0027627Neoplasm Metastasis1CTD_human
TgeneYWHAEC0265219Miller Dieker syndrome1ORPHANET
TgeneYWHAEC0334488Clear cell sarcoma of kidney1ORPHANET
TgeneYWHAEC2750748Chromosome 17p13.3 Duplication Syndrome1ORPHANET
TgeneYWHAEC4707092Distal 17p13.3 microdeletion syndrome1ORPHANET